Introduction

I. Company Profile

Lihero Pharmaceutical Co., Ltd (hereinafter referred to as "Lihero Pharmaceutical") was established in November 2019. The company is located in Zhumadian High-tech Zone, Henan Province, covering an area of 211 mu. It is a modern pharmaceutical enterprise engaged in the research, development, production and sales of intermediates, bulk drugs and pharmaceutical preparations. The company has more than 180 employees, more than 75% of whom have college education or above, and more than 30% of the company's professional talents. With superb technology and rich experience, it has become the backbone of enterprise innovation and development.

II. Company Honor

The company always insists on quality first and scientific and technological innovation, and has made remarkable achievements in lean, professional and new quality. At present, it has won the honorary titles of National High-tech Enterprise, Henan Engineering Technology Research Center, Henan Youth Employment Trainee Unit, Henan Specialized Small and Medium-sized Enterprise, Zhumadian Intellectual Property Advantage Enterprise, Zhumadian Enterprise Technology Center and Zhumadian Three-Star Industrial Enterprise.

III. Main products of the company

The company now has product lines of cephalosporin intermediates, APIs and preparations. The main products are Descarbamoyl Cefuroxime Acid, Cefuroxime Acid, Cefuroxime Axetil, Sodium Flomoxef, Cefditoren Pivoxil, and so on. The above products have mature sales channels at home and abroad.

IV. Technical Development and Cooperation

Innovation drives development. In terms of hardware, the company introduces production and inspection equipment from Italy, the United States, Denmark, Germany, Japan and other countries. In terms of software, according to GMP and ICH Q7 standards, a scientific quality assurance system is established from supplier evaluation and selection, material purchase and control, production process quality control to after-sales service quality tracking. The existing scientific research base covers an area of 1,300 ㎡ and the pilot plant covers an area of 2,800 ㎡. The total value of testing, analysis, inspection and other instruments and equipment is 16 million yuan. The instruments and equipment are fully functional and can meet the needs of scientific research and experiments.

The company has established a special R&D center with 20 employees, all of whom have rich R&D experience and undertake the task of product process development, improvement and optimization. R&D projects mainly focus on the process optimization and upgrading of existing products and the process development of intermediates, APIs and preparations. At present, the R&D center has completed a number of R&D projects and applied for 27 patents, of which 19 have been authorized.

In terms of technology development and cooperation, the company has carried out in-depth cooperation with well-known domestic research institutes and universities to form an extension and expansion of the product industry chain. Through the development of cooperative projects, the company has gradually moved towards the development stage of production and R&D, and established a control system for the whole process of drug R&D covering intermediates, APIs and preparations from project establishment to marketing.

V. Vision and prospect

Lihero Pharmaceutical is marching towards a brand enterprise with high-tech content, high market share and high enterprise competitiveness with lean enterprise management, professional pharmaceutical industry and three-dimensional customer service as the direction. Looking forward to the future, Linuo Pharmaceutical will continue to strengthen and promote innovation, making the company an innovative pharmaceutical enterprise with extensive influence and respect at home and abroad.